NCT02308839

GORE® EXCLUDER® Endoprosthesis French Mandatory Registry

Study of the GORE® EXCLUDER® Endoprosthesis in the Treatment of Infra-renal Abdominal Aortic Aneurysms

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 181 (actual)
• Sponsor: W.L.Gore & Associates · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a French Registry mandated by the French National Health Authority assessing long-term (5-years) safety of the GORE® Excluder® Endoprosthesis in the treatment of infra-renal Abdominal Aortic Aneurysms (AAA).

Detailed description

The use of abdominal aortic endoprostheses makes the treatment of infra-renal abdominal aortic aneurysms possible, with implantation via the femoral artery, thus avoiding a very invasive surgical procedure. The French National Authority for Health requires a 5-year follow-up as part of the renewal for reimbursement for these endoprostheses.

Conditions

• Abdominal Aortic Aneurysm

Interventions

Type	Name	Description
DEVICE	GORE® EXCLUDER® Endoprosthesis	Endovascular therapy to treat abdominal aortic aneurysms

Timeline

• Start date: 2012-07-01
• Primary completion: 2018-09-26
• Completion: 2018-10-05
• First posted: 2014-12-04
• Last updated: 2020-05-22
• Results posted: 2020-05-22

Locations

1 site across 1 country: France